Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis

Abstract

BACKGROUND Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity. CASES PRESENTATION We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing. CONCLUSIONS Pazopanib is an active treatment in DT/AF. It is the first time this has been reported.